| Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma T Casneuf, XS Xu, HC Adams III, AE Axel, C Chiu, I Khan, T Ahmadi, ... Blood advances 1 (23), 2105-2114, 2017 | 191 | 2017 |
| Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models X Yan, DE Mager, W Krzyzanski Journal of pharmacokinetics and pharmacodynamics 37, 25-47, 2010 | 97 | 2010 |
| Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment PL Clemens, X Yan, HM Lokhorst, S Lonial, N Losic, I Khan, R Jansson, ... Clinical pharmacokinetics 56, 915-924, 2017 | 76 | 2017 |
| Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges H Zou, P Banerjee, SSY Leung, X Yan Frontiers in pharmacology 11, 543082, 2020 | 75 | 2020 |
| Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma XS Xu, X Yan, T Puchalski, S Lonial, HM Lokhorst, PM Voorhees, ... Clinical Pharmacology & Therapeutics 101 (6), 721-724, 2017 | 67 | 2017 |
| Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic … MC Genovese, E Hsia, SM Belkowski, C Chien, T Masterson, ... The Journal of rheumatology 42 (10), 1752-1760, 2015 | 58 | 2015 |
| Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations S Willmann, L Zhang, M Frede, D Kubitza, W Mueck, S Schmidt, A Solms, ... CPT: Pharmacometrics & Systems Pharmacology 7 (5), 309-320, 2018 | 56 | 2018 |
| Population pharmacokinetic and pharmacodynamic model‐based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575 X Yan, PJ Lowe, M Fink, A Berghout, S Balser, W Krzyzanski The Journal of Clinical Pharmacology 52 (11), 1624-1644, 2012 | 45 | 2012 |
| Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor X Yan, Y Chen, W Krzyzanski Journal of pharmacokinetics and pharmacodynamics 39, 543-560, 2012 | 38 | 2012 |
| Influence of disease and patient characteristics on daratumumab exposure and clinical outcomes in relapsed or refractory multiple myeloma X Yan, PL Clemens, T Puchalski, S Lonial, H Lokhorst, PM Voorhees, ... Clinical pharmacokinetics 57, 529-538, 2018 | 28 | 2018 |
| Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs Y Zhang, C Lyu, SYK Fong, Q Wang, C Li, NJ Ho, KS Chan, X Yan, Z Zuo Journal of ethnopharmacology 243, 112097, 2019 | 22 | 2019 |
| Target-mediated drug disposition of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory … X Yan, PL Clemens, T Puchalski, S Lonial, HM Lokhorst, RZ Orlowski, ... Blood, The Journal of the American Society of Hematology 126 (23), 4222-4222, 2015 | 22 | 2015 |
| Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation L Zhang, X Yan, KAA Fox, S Willmann, P Nandy, SD Berkowitz, ... Journal of Thrombosis and Thrombolysis 50, 20-29, 2020 | 17 | 2020 |
| Quantitative assessment of minimal effective concentration of erythropoiesis‐stimulating agents X Yan, W Krzyzanski CPT: Pharmacometrics & Systems Pharmacology 2 (8), 1-10, 2013 | 13 | 2013 |
| Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness X Yan, S Ait-Oudhia, W Krzyzanski Pharmaceutical research 30, 1026-1036, 2013 | 13 | 2013 |
| Reduced systemic and brain exposure with inhibited liver metabolism of carbamazepine after its long-term combination treatment with piperine for epilepsy control in rats T Ren, M Xiao, M Yang, J Zhao, Y Zhang, M Hu, Y Cheng, H Xu, C Zhang, ... The AAPS journal 21, 1-16, 2019 | 12 | 2019 |
| Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens R D'Cunha, R Schmidt, JA Widness, DM Mock, X Yan, GA Cress, ... European journal of pharmaceutical sciences 138, 105013, 2019 | 11 | 2019 |
| Pharmacodynamic relationship between natural killer cells and daratumumab exposure in relapsed/refractory multiple myeloma T Casneuf, XS Xu, HIII Adams, A Axel, B Verbist, K Liu, I Khan, T Ahmadi, ... Haematologica 101, 87-88, 2016 | 10 | 2016 |
| Dose correction for the Michaelis–Menten approximation of the target-mediated drug disposition model X Yan, W Krzyzanski Journal of pharmacokinetics and pharmacodynamics 39, 141-146, 2012 | 10 | 2012 |
| Enhancing the quality of rivaroxaban exposure estimates using prothrombin time in the absence of pharmacokinetic sampling A Solms, M Frede, SD Berkowitz, A Hermanowski‐Vosatka, D Kubitza, ... CPT: Pharmacometrics & Systems Pharmacology 8 (11), 805-814, 2019 | 9 | 2019 |
Steven XuJanssen R&DVerified email at its.jnj.com
